CYP3A4 expression to predict treatment response to docetaxel for metastasis and recurrence of primary breast cancer

Surgery Today

Volumn 41, Issue 5, 2011, Pages 674-679

  Sakurai, Kenichi ^a   Enomoto, Katsuhisa ^a   Matsuo, Sadanori ^a   Amano, Sadao ^a   Shiono, Motomi ^a  

^a NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Breast cancer; Chemotherapy; CYP3A4; Docetaxel; Recurrence

Indexed keywords

AROMATASE INHIBITOR; CYCLOPHOSPHAMIDE; CYTOCHROME P450 3A4; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; PROGESTERONE RECEPTOR; TAMOXIFEN; TRASTUZUMAB;

ADULT; AGED; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER RECURRENCE; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; HUMAN; IMMUNOHISTOCHEMISTRY; METASTASIS; NONHUMAN; PREDICTIVE VALUE; PROTEIN ANALYSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARCINOMA; CYTOCHROME P-450 CYP3A; DISEASE PROGRESSION; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; TAXOIDS; TREATMENT OUTCOME;

EID: 79956201210     PISSN: 09411291     EISSN: 14362813     Source Type: Journal    
DOI: 10.1007/s00595-009-4328-7     Document Type: Article

References (29)

1. Campone M, Campion L, Roche H, Gouraud W, Charbonnel C, Magrangeas F, et al. Prediction of metastatic relapse in nodepositive breast cancer: establishment of a clinicogenomic model after FEC100 adjuvant regimen. Breast Cancer Res Treat 2008;109:491-501. (Pubitemid 351692060)
2. Ten Bokkel Huinink WW, Prove AM, Piccart M, Steward W, Tursz T, Wanders J, et al. A phase II trial with docetaxel (Taxotere) in second line treatment with chemotherapy for advanced breast cancer. A study of the EORTC Early Clinical Trials Group. Ann Oncol 1994;5:527-32.
3. Eisenhauer EA, Trudeau M. An overview of phase II studies of docetaxel in patients with metastatic breast cancer. Eur J Cancer 1995;31A Suppl 4:S11-3.
4. Ravdin PM. Docetaxel (Taxotere) for the treatment of anthracycline- resistant breast cancer. Semin Oncol 1997;24:S10-18-21.
5. Hudis CA, Seidman AD, Crown JP, Balmaceda C, Freilich R, Gilewski TA, et al. Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer. J Clin Oncol 1996;14:58-65.
6. Veneroni S, Zaffaroni N, Daidone MG, Benini E, Villa R, Silvestrini R. Expression of P-glycoprotein and in vitro or in vivo resistance to doxorubicin and cisplatin in breast and ovarian cancers. Eur J Cancer 1994;30A:1002-7. (Pubitemid 24256252)
7. Hasegawa S, Miyoshi Y, Egawa C, Ishitobi M, Taguchi T, Tamaki Y, et al. Prediction of response to docetaxel by quantitative analysis of class I and III beta-tubulin isotype mRNA expression in human breast cancers. Clin Cancer Res 2003;9:2992-7. (Pubitemid 36993258)
8. Egawa C, Miyoshi Y, Taguchi T, Tamaki Y, Noguchi S. High BRCA2 mRNA expression predicts poor prognosis in breast cancer patients. Int J Cancer 2002;98:879-82. (Pubitemid 34286684)
9. Miyoshi Y, Ando A, Takamura Y, Taguchi T, Tamaki Y, Noguchi S. Prediction of response to docetaxel by CYP3A4 mRNA expression in breast cancer tissues. Int J Cancer 2002;97:129-32.
10. Honma K, Iwao-Koizumi K, Takeshita F, Yamamoto Y, Yoshida T, Nishio K, et al. RPN2 gene confers docetaxel resistance in breast cancer. Nat Med 2008;939-48.
11. Commercon A, Bourzat JD, Bezard JD, Vuilhorgne M. Partial synthesis of major human metabolites of docetaxel. Tetrahedron 1994;50:10289-98. (Pubitemid 24274461)
12. Miyoshi Y, Taguchi T, Kim SJ, Tamaki Y, Noguchi S. Prediction of response to docetaxel by immunohistochemical analysis of CYP3A4 expression in human breast cancers. Breast Cancer 2005;12:11-5.
13. Crump M, Sawka CA, DeBoer G, Buchanan RB, Ingle JN, Forbes J, et al. An individual patient-based meta-analysis of tamoxifen versus ovarian ablation as first line endocrine therapy for premenopausal women with metastatic breast cancer. Breast Cancer Res Treat 1997;44:201-10. (Pubitemid 27296379)
14. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999;17:2639-48. (Pubitemid 29415219)
15. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-16. (Pubitemid 30099779)
16. Kirches E, Scherlach C, von Bossanyi P, Schneider T, Szibor R, Kutz E, et al. MGMT- and P450 3A-inhibitors do not sensitize glioblastoma cell cultures against nitrosoureas. Clin Neuropathol 1999;18:1-8. (Pubitemid 29039721)
17. Gligorov J, Lotz JP. Optimal treatment strategies in postmenopausal women with hormone-receptor-positive and HER2-negative metastatic breast cancer. Breast Cancer Res Treat 2008;Suppl 1:53-66.
18. Fisher B, Dignam J, Bryant J, Wolmark N. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst 2001;93:684-90. (Pubitemid 32492809)
19. Bast RC Jr, Ravdin P, Hayes DF, Bates S, Fritsche H Jr, Jessup JM, et al. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001;19:1865-78. (Pubitemid 32230890)
20. Burkhart CA, Kavallaris M, Horwitz SB. The role of beta-tublin isotype in resistance to antimitotic drugs. Biochim Biophys Acta 2002;1471:1-9.
21. Simon S, Stieger B, Kullak-Ublick GA, Fried M, Mueller S, Fritschy JM, et al. Intestinal expression of cytochrome P450 enzymes and ABC transporters and carbamazepine and phenytoin disposition. Acta Neurol Scand 2007;115:232-42. (Pubitemid 46449584)
22. Waxman DJ. P450 gene induction by structurally diverse xenochemicals: central role of nuclear receptors CAR, PXR, and PPAR. Arch Biochem Biophys 1999;369:11-23. (Pubitemid 29434534)
23. Sonoda J, Xie W, Rosenfeld JM, Barwick JL, Guzelian PS, Evans RM. Regulation of a xenobiotic sulfonation cascade by nuclear pregnane X receptor (PXR). Proc Natl Acad Sci USA 2002;99:13801-6. (Pubitemid 35215461)
24. Fujimura T, Takahashi S, Urano T, Kumagai J, Murata T, Takayama K, et al. Expression of cytochrome P450 3A4 and its clinical signifi cance in human prostate cancer. Urology 2009;74(2):391-7.
25. Tan SH, Lee SC, Goh BC, Wong J. Pharmacogenetics in breast cancer therapy. Clin Cancer Res 2008;14:8027-41.
26. Huang Z, Fasco MJ, Figge HL, Keyomarsi K, Kaminsky LS. Expression of cytochromes P450 in human breast tissue and tumors. Drug Metab Dispos 1996;24:899-905. (Pubitemid 26274749)
27. Kapucuoglu N, Coban T, Raunio H, Pelkonen O, Edwards RJ, Boobis AR, et al. Expression of CYP3A4 in human breast tumour and non-tumour tissues. Cancer Lett 2003;202:17-23. (Pubitemid 37464894)
28. Fisher B, Anderson S, Tan-Chiu E, Wolmark N, Wickerham DL, Fisher ER, et al. Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23. J Clin Oncol 2001;19:931-42. (Pubitemid 32176267)
29. Fujitaka K, Oguri T, Isobe T, Fujiwara Y, Kohno N. Induction of cytochrome P450 3A4 by docetaxel in peripheral mononuclear cells and its expression in lung cancer. Cancer Chemother Pharmacol 2001;48:42-6. (Pubitemid 32662435)